Results 171 to 180 of about 52,475 (270)

Dose Optimization of Rivaroxaban in Elderly Chinese Patients with Non-Valvular Atrial Fibrillation: Analysis of Populations Pharmacokinetics and Exposure-Response Relationships. [PDF]

Drug Des Devel Ther
Li TY, Liu X, Tang L, Cai W, Zhang J, Su Y, Yu C, Liu BJ, Jiang LF, Liu C, Yu YX.   +10 more
europepmc   +1 more source

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

, 2015
Sameer Bansilal, Zachary T. Bloomgarden, Jonathan L. Halperin, Anne S. Hellkamp, Yuliya Lokhnygina, Manesh R. Patel, Richard C. Becker, Günter Breithardt, Werner Hacke, Graeme J. Hankey, Christopher C. Nessel, Daniel E. Singer, Scott D. Berkowitz, Jonathan P. Piccini, Kenneth W. Mahaffey, Keith A.A. Fox   +15 more
openalex   +1 more source

Enhanced Nutritional Support May Ameliorate Rivaroxaban-Related Rapid Renal Function Decline: New Insights from a Real-World Study. [PDF]

Drug Des Devel Ther
Meng C, Li L, Han Y, Zhang X, Lin Y, Liu H, Jiang S, Yan T, Zhang L, Chang B, Zhou X, Jia J.   +11 more
europepmc   +1 more source

Multicenter Evaluation of Different Anti-Xa Assays and Diluted Russell's Viper Venom Time in Ex Vivo Plasma Samples from Patients Treated with Rivaroxaban or Apixaban. [PDF]

J Clin Med
Božič Mijovski M, Mavri A, Antovic JP, Malmström RE, Coen Herak D.   +4 more
europepmc   +1 more source

Inhibition of FXa could be a novel therapeutic target associated with hypoxia-associated tumor behavior? [PDF]

Discov Oncol
Bayrak O, Mert N, Basbinar Y, Bayrak S.
europepmc   +1 more source

Comparing the Efficacy and Safety of Different DOACs (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) for Stroke Prevention in Atrial Fibrillation [PDF]

Dinesh Balamurugan, Collins Gilbert, Michael A�mann, Harsh Bansal   +3 more
openalex   +1 more source

Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study. [PDF]

Cancer Immunol Immunother
Zhang H, Li J, Yuan G, Huang S, Li X.
europepmc   +1 more source

Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study

Wei Meng, Xue Wu, Liteng Wang, Zhi‐Chun Gu, Yuanmao Tu, Lihua Zhang, Jiong Zhang, Honglang Xie, Qing Zhou, Yanan Chu, Cheng Zhen, Guohua Zhou, Qinxin Song   +12 more
openalex   +1 more source

Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective [PDF]

, 2018
Ella Zomer, Si Si, Thomas R. Hird, Danny Liew, Alice Owen, Andrew Tonkin, Christopher M. Reid, Zanfina Ademi   +7 more
openalex   +1 more source

Safety and Efficacy of Rivaroxaban Versus Warfarin in Cerebral Venous Thrombosis: A Comprehensive Meta-Analysis. [PDF]

Neurol Int
Ranjan R, Ken-Dror G.
europepmc   +1 more source